Pharvaris up as FDA lifts hold on skin disease drug study

Pharvaris NV

26/06/2023 17:17

** Shares of Pharvaris  PHVS.O  rise 14.7% to $13.3
    ** Drug developer said U.S. FDA has lifted clinical hold on
application to initiate study of its experimental drug to treat
and prevent hereditary angioedema (HAE) attacks
    ** FDA's decision is based on reviewing data from an interim
analysis of a non-clinical study, complete data from which is
expected to be presented by end of 2023 
     ** HAE is a disease characterized by recurrent episodes of
severe swelling of the skin and mucous membranes
    ** Including session's gain, stock up ~18% YTD 

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))